文献速递肝病消化道肿瘤与早癌

RTN3介导的Chk2/p53激活抑制肝细胞癌发生且被HBV阻断

Reticulon 3-mediated Chk2/p53 activation suppresses hepatocellular carcinogenesis and is blocked by hepatitis B virus.
PubMed 文献 · Gut · 2020-12-10

该研究探讨内质网蛋白RTN3在肝细胞癌中的作用。临床样本显示RTN3在正常肝细胞高表达而在HCC中常下调,低表达预示不良预后且与TP53突变和HBV感染状态相关。机制上RTN3通过Chk2促进p53 Ser392磷酸化并增强p53核定位,但HBV表面抗原竞争性结合RTN3阻断该通路。

要点

  • RTN3在正常肝细胞高表达,在HCC中常下调,低表达预示不良预后。
  • RTN3通过Chk2促进p53 Ser392磷酸化并增强p53核定位来抑制HCC。
  • HBV表面抗原竞争结合RTN3,阻断RTN3介导的Chk2/p53激活。

核心结论

  • RTN3通过激活Chk2/p53通路发挥新型HCC抑制因子作用,并揭示HBV的致癌效应机制。

研究设计与样本

  • 收集临床HCC样本评估RTN3表达与患者结局的关系。
  • 使用HCC细胞系体外检测RTN3对增殖、凋亡和信号转导的影响。
  • 采用裸鼠模型体内检测RTN3对肿瘤生长的调节作用。

主要发现

  • RTN3在正常肝细胞高表达但在HCC中频繁下调。
  • 低RTN3表达以TP53基因突变和HBV感染状态依赖的方式预示HCC患者不良结局。
  • RTN3通过激活p53抑制HCC生长并诱导凋亡。
  • RTN3以ER钙依赖方式与Chk2互作,招募其至ER并促进激活。
  • HBV表面抗原与Chk2竞争结合RTN3,阻断RTN3介导的Chk2/p53激活。

临床怎么用

  • RTN3低表达可作为HCC预后不良的潜在标志物,需结合TP53突变和HBV感染状态解读。
  • 靶向RTN3-Chk2-p53轴可能为HCC治疗提供新思路,但HBV阳性患者可能疗效受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Dysfunction of endoplasmic reticulum (ER) proteins is closely related to homeostasis disturbance and malignant transformation of hepatocellular carcinoma (HCC). Reticulons (RTN) are a family of ER-resident proteins critical for maintaining ER function. Nevertheless, the precise roles of RTN in HCC remain largely unclear. The aim of the study is to examine the effect of reticulon family member RTN3 on HCC development and explore the underlying mechanisms. DESIGN: Clinical HCC samples were collected to assess the relationship between RTN3 expression and patients' outcome. HCC cell lines were employed to examine the effects of RTN3 on cellular proliferation, apoptosis and signal transduction in vitro. Nude mice model was used to detect the role of RTN3 in modulating tumour growth in vivo. RESULTS: We found that RTN3 was highly expressed in normal hepatocytes but frequently downregulated in HCC. Low RTN3 expression predicted poor outcome in patients with HCC in TP53 gene mutation and HBV infection status-dependent manner. RTN3 restrained HCC growth and induced apoptosis by activating p53. Mechanism studies indicated that RTN3 facilitated p53 Ser392 phosphorylation via Chk2 and enhanced subsequent p53 nuclear localisation. RTN3 interacted with Chk2, recruited it to ER and promoted its activation in an ER calcium-dependent manner. Nevertheless, the tumour suppressive effects of RTN3 were abrogated in HBV-positive cells. HBV surface antigen competed with Chk2 for RTN3 binding and blocked RTN3-mediated Chk2/p53 activation. CONCLUSION: The findings suggest that RTN3 functions as a novel suppressor of HCC by activating Chk2/p53 pathway and provide more clues to better understand the oncogenic effects of HBV.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Song S, Shi Y, Wu W, et al. Reticulon 3-mediated Chk2/p53 activation suppresses hepatocellular carcinogenesis and is blocked by hepatitis B virus. Gut. 2020. PMID: 33303565. doi:10.1136/gutjnl-2020-321386

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。